Eva Haglind1, Stefan Carlsson2, Johan Stranne3, Anna Wallerstedt2, Ulrica Wilderäng4, Thordis Thorsteinsdottir5, Mikael Lagerkvist6, Jan-Erik Damber3, Anders Bjartell7, Jonas Hugosson3, Peter Wiklund2, Gunnar Steineck8. 1. Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg and Sahlgrenska University Hospital, Göteborg, Sweden. Electronic address: eva.haglind@vgregion.se. 2. Department of Molecular Medicine and Surgery, Section of Urology, Karolinska Institutet, Stockholm, Sweden. 3. Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Göteborg, Sweden. 4. Division of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Göteborg, Sweden. 5. Division of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Göteborg, Sweden; Faculty of Nursing, School of Health Sciences, University of Iceland, Reykjavík, Iceland. 6. UroClinic, Stockholm, Sweden. 7. Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden. 8. Division of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Göteborg, Sweden; Department of Oncology and Pathology, Division of Clinical Cancer Epidemiology, Karolinska Institutet, Stockholm, Sweden.